Triple-negative breast cancers (TNBC), which do not express any of these targets, i.e., estrogen receptor, progesterone receptor, and HER2 receptor, are the most challenging to treat as these show a poor response to both HER2 targeted and hormonal receptor (estrogen, and progesterone receptor) targeted therapies. This evidence concerns the gene PGR and triple-negative breast carcinoma.